Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Search
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Announces the Launch of Centragard™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats
Boehringer Ingelheim Announces the Launch of Centragard™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats
How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health
Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Asthmatic Horse's First Inhaled Therapy | Boehringer Ingelheim US
Click here to read about Boehringer Ingelheim launching the first inhaled therapy for horses suffering with severe asthma in the United States.
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Company History | Corporate Profile | Boehringer Ingelheim US
Click here to watch our video on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885.
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
A legacy in the making: Working together to spark meaningful change
Discover Jim’s passion for being an advocate for meaningful causes.
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Boehringer Ingelheim announces InPedILD PhaseIII trial results
BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US
BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.
BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
USDA & BI Expand Research Opportunities | Boehringer Ingelheim US
Find out more about how veterinary students will work with USDA scientists in researching emerging diseases related to both animal and public health.
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity